3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis.

Journal of neuroimmunology 20120401

Recurrent COLQ mutation in congenital myasthenic syndrome.

Pediatric neurology 20120401

The dynamic relationships between the three events that release individual Na⁺ ions from the Na⁺/K⁺-ATPase.

Nature communications 20120214

Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.

Journal of clinical pharmacy and therapeutics 20120201

Clinical features in a series of fast channel congenital myasthenia syndrome.

Neuromuscular disorders : NMD 20120201

Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: Results of a patient interview survey in Germany.

Journal of medical economics 20120101

Hypotension due to Chemotherapy in a Patient with Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome Undergoing Hemodialysis: A First Case Report.

Case reports in oncology 20120101

Nervous System of Periplaneta americana Cockroach as a Model in Toxinological Studies: A Short Historical and Actual View.

Journal of toxicology 20120101

The use of aminopyridines in neurological disorders.

Clinical neuropharmacology 20120101

The Effects of K(+) Channel Blockade on Eccentric and Isotonic Twitch and Fatiguing Contractions in situ.

Frontiers in physiology 20120101

[Aminopyridines for symptomatic treatment of multiple sclerosis].

Ugeskrift for laeger 20111212

Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20111201

John Newsom-Davis: clinician-scientist and so much more.

Brain : a journal of neurology 20111201

Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.

Neurology 20111108

Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

Bioorganic & medicinal chemistry 20111101

One collective case of type A foodborne botulism in Corsica.

Clinical toxicology (Philadelphia, Pa.) 20111001

Role of calcium-activated potassium channels in the genesis of 3,4-diaminopyridine-induced periodic contractions in isolated canine coronary artery smooth muscles.

The Journal of pharmacology and experimental therapeutics 20110901

Autoimmune neuromuscular disorders.

Current neuropharmacology 20110901

Autoimmune channelopathies of the nervous system.

Current neuropharmacology 20110901

Aminopyridines correct early dysfunction and delay neurodegeneration in a mouse model of spinocerebellar ataxia type 1.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20110817

Single-pixel optical fluctuation analysis of calcium channel function in active zones of motor nerve terminals.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20110803

Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.

Muscle & nerve 20110801

Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus.

Journal of neurology 20110701

Preclinical evaluation of caprylic acid-fractionated IgG antivenom for the treatment of Taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea.

PLoS neglected tropical diseases 20110501

Medical treatment for botulism.

The Cochrane database of systematic reviews 20110316

Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.

Journal of clinical neuromuscular disease 20110301

Treatment for Lambert-Eaton myasthenic syndrome.

The Cochrane database of systematic reviews 20110216

A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel function.

The Journal of biological chemistry 20110128

Protein kinases modulate store-operated channels in pulmonary artery smooth muscle cells.

Journal of biomedical science 20110101

Suramin inhibits the early effects of PLA(2) neurotoxins at mouse neuromuscular junctions: A twitch tension study.

Journal of venom research 20110101

Pricing and reimbursement of orphan drugs: the need for more transparency.

Orphanet journal of rare diseases 20110101

Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Neuropsychiatric disease and treatment 20110101

The neuromuscular activity of Micrurus pyrrhocryptus venom and its neutralization by commercial and specific coral snake antivenoms.

Journal of venom research 20110101

Cerebellum and ocular motor control.

Frontiers in neurology 20110101

Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.

Autoimmune diseases 20110101

Symptomatic relief of botulinum neurotoxin/a intoxication with aminopyridines: a new twist on an old molecule.

ACS chemical biology 20101217

Orphan drugs. BioMarin Europe replies.

BMJ (Clinical research ed.) 20101207

Orphan drugs. Regulation is flawed.

BMJ (Clinical research ed.) 20101207

3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.

Expert review of clinical immunology 20101101

3,4-Diaminopyridinium 2-carboxy-4,6-dinitrophenolate.

Acta crystallographica. Section E, Structure reports online 20101101

State of the art in hereditary muscle channelopathies.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 20101001

Anharmonic vibrational analysis of 3,4-diaminopyridine and 3-aminopyridine by density functional theory calculations.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20100901

The price you pay.

Drug and therapeutics bulletin 20100901

3-D-QSAR and docking studies on the neuronal choline transporter.

Bioorganic & medicinal chemistry letters 20100815

Guidelines for treatment of autoimmune neuromuscular transmission disorders.

European journal of neurology 20100701

Lambert-Eaton myasthenic syndrome as a cause of persistent neuromuscular weakness after a mediastinoscopic biopsy -A case report-.

Korean journal of anesthesiology 20100701

Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.

Human molecular genetics 20100615

3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.

Journal of neurology 20100601

Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.

Neuropharmacology 20100601

Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.

Current medical research and opinion 20100601

The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.

Journal of the neurological sciences 20100515

Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

Neurology 20100511

The zinc-dependent protease activity of the botulinum neurotoxins.

Toxins 20100501

[Lambert-Eaton myasthenic syndrome (LEMS)].

Brain and nerve = Shinkei kenkyu no shinpo 20100401

Neuropharmacology of vestibular system disorders.

Current neuropharmacology 20100301

4-Amino-3-ammonio-pyridinium dinitrate.

Acta crystallographica. Section E, Structure reports online 20100301

Quantification of 4-aminopyridine in plasma by capillary electrophoresis with electrokinetic injection.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201

Effect of pantoprazole and its interactions with vecuronium on the neuromuscular junction.

Indian journal of pharmacology 20100201

Improvement of diaphragm and limb muscle isotonic contractile performance by K+ channel blockade.

Journal of neuroengineering and rehabilitation 20100101

[Lambert-Eaton myasthenic syndrome associated with pulmonary squamous cell carcinoma and circulating anti-P/Q-type voltage-gated calcium channel antibody].

Rinsho shinkeigaku = Clinical neurology 20100101

New methods for diagnosis and treatment of vestibular diseases.

F1000 medicine reports 20100101

Eye disorders in patients with multiple sclerosis: natural history and management.

Clinical ophthalmology (Auckland, N.Z.) 20100101

Sensing the deadliest toxin: technologies for botulinum neurotoxin detection.

Toxins 20100101

Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties.

Nanotechnology 20091111

3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.

Muscle & nerve 20091101

{2,2'-[Pyridine-3,4-diylbis(nitrilo-methyl-idyne)]diphenolato}zinc(II).

Acta crystallographica. Section E, Structure reports online 20091101

Management of myasthenic conditions: nonimmune issues.

Current opinion in neurology 20091001

3,4-Diamino-pyridinium 4-nitro-benzoate-4-nitro-benzoic acid (1/1).

Acta crystallographica. Section E, Structure reports online 20090801

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Clinical pharmacology and therapeutics 20090701

Skeletal muscle contraction-induced vasodilator complement production is dependent on stimulus and contraction frequency.

American journal of physiology. Heart and circulatory physiology 20090701

3,4-Diamino-pyridinium hydrogen succinate.

Acta crystallographica. Section E, Structure reports online 20090701

Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome.

Journal of medical genetics 20090301

[Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency].

No to hattatsu = Brain and development 20090101

[A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20090101

4-Amino-3-ammonio-pyridinium dichloride.

Acta crystallographica. Section E, Structure reports online 20090101

[Pharmacotherapy of central oculomotor disorders].

Der Nervenarzt 20081201

Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation.

Muscle & nerve 20081201

Therapeutic strategies in congenital myasthenic syndromes.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20081001

Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.

Journal of neuroimmunology 20080915

Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression.

Brain structure & function 20080901

Mechanisms of neuromodulation as dissected using Sr2+ at motor nerve endings.

Journal of neurophysiology 20080601

Onset dynamics of type A botulinum neurotoxin-induced paralysis.

Journal of pharmacokinetics and pharmacodynamics 20080601

Inotropic effects of the K+ channel blocker 3,4-diaminopyridine on fatigued diaphragm muscle.

Respiratory physiology & neurobiology 20080101

[Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma].

Revue neurologique 20080101

L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle.

PloS one 20080101

Autoantibodies in neuromuscular transmission disorders.

Annals of Indian Academy of Neurology 20080101

[Successful treatment of a Lambert-Eaton myasthenic syndrome patient with 3,4-diaminopyridine].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070810

Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion.

Journal of neurology 20070801

Childhood myasthenia: clinical subtypes and practical management.

Developmental medicine and child neurology 20070801

Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.

Muscle & nerve 20070701

Potassium initiates vasodilatation induced by a single skeletal muscle contraction in hamster cremaster muscle.

The Journal of physiology 20070601

Molecular docking study of the binding of aminopyridines within the K+ channel.

Journal of molecular modeling 20070501

Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.

The European journal of neuroscience 20070501

The therapy of congenital myasthenic syndromes.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20070401

Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products.

Journal of pharmaceutical and biomedical analysis 20070104

[Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101

Inotropic effects of the K+ channel blocker 3,4-diaminopyridine: differential responses of rat soleus and extensor digitorum longus.

IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society 20061201

Altered diaphragm muscle action potentials in Zucker diabetic fatty (ZDF) rats.

Respiratory physiology & neurobiology 20060928

Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.

Neurology 20060912

Extrusion of Ca2+ from mouse motor terminal mitochondria via a Na+-Ca2+ exchanger increases post-tetanic evoked release.

The Journal of physiology 20060801

Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'.

Brain : a journal of neurology 20060801

Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.

Pharmacology & therapeutics 20060701

Available treatment options for the management of Lambert-Eaton myasthenic syndrome.

Expert opinion on pharmacotherapy 20060701

Guidelines for the treatment of autoimmune neuromuscular transmission disorders.

European journal of neurology 20060701

No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.

Neurology 20060613

The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction.

The European journal of neuroscience 20060601

Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome.

The Annals of pharmacotherapy 20060401

[Fatigue and episodic exhaustion as a feature of multiple sclerosis].

Revue neurologique 20060301

[Pathophysiology and treatment of fatigue in multiple sclerosis].

Revue neurologique 20060301

NCAM 180 acting via a conserved C-terminal domain and MLCK is essential for effective transmission with repetitive stimulation.

Neuron 20050616

Taicatoxin inhibits the calcium-dependent slow motility of mammalian outer hair cells.

Hearing research 20050501

Treatment for Lambert-Eaton myasthenic syndrome.

The Cochrane database of systematic reviews 20050418

Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.

Annals of the New York Academy of Sciences 20050401

Cognitive deficits in aged rats correlate with levels of L-arginine, not with nNOS expression or 3,4-DAP-evoked transmitter release in the frontoparietal cortex.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20050301

Electrophysiological and pharmacological characterization of K+-currents in muscle fibres isolated from the ventral sucker of Fasciola hepatica.

Parasitology 20041201

Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries.

Hypertension (Dallas, Tex. : 1979) 20040901

Upbeat about downbeat nystagmus.

Neurology 20040824

Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus.

Neurology 20040824

Determination of A 3,4-diaminopyridine in plasma by liquid chromatography with electrochemical detection using solid-phase extraction.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615

Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.

Neurology 20040608

Distinct phenotypes of congenital acetylcholine receptor deficiency.

Neuromuscular disorders : NMD 20040601

Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage.

Journal of neurology, neurosurgery, and psychiatry 20040601

Cure of experimental botulism and antibotulismic effect of toosendanin.

Acta pharmacologica Sinica 20040601

Combination of variable frequency train stimulation and K+ channel blockade to augment skeletal muscle force.

IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society 20040601

Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation.

Pharmacology, biochemistry, and behavior 20040301

Novel truncating RAPSN mutations causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine.

Neuromuscular disorders : NMD 20040301

Lambert-Eaton myasthenic syndrome.

Revue neurologique 20040201

3,4-DAP-evoked transmitter release in hippocampal slices of aged rats with impaired memory.

Brain research bulletin 20031215

[Formulation and stability of hospital preparation of 3,4-diaminopyridine capsules].

Annales pharmaceutiques francaises 20031101

Sternohyoid muscle fatigue properties of dy/dy dystrophic mice, an animal model of merosin-deficient congenital muscular dystrophy.

Pediatric research 20031001

Lambert-eaton myasthenic syndrome: diagnosis and treatment.

Annals of the New York Academy of Sciences 20030901

Wheel-running exercise alters rat diaphragm action potentials and their regulation by K+ channels.

Journal of applied physiology (Bethesda, Md. : 1985) 20030801

Potassium channels, the cerebellum, and treatment for downbeat nystagmus.

Neurology 20030722

Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.

Neurology 20030722

Rational modelling of the voltage-dependent K+ channel inactivation by aminopyridines.

Biophysical chemistry 20030601

Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Seminars in neurology 20030601

The vascular response to the K+ channel inhibitor 4-aminopyridine in hypertensive rats.

European journal of pharmacology 20030418

Streptozotocin-diabetes alters action potentials in rat diaphragm.

Respiratory physiology & neurobiology 20030415

Quantitative estimate of mitochondrial [Ca2+] in stimulated motor nerve terminals.

Cell calcium 20030301

Membrane properties related to the firing behavior of zebrafish motoneurons.

Journal of neurophysiology 20030201

Exacerbation of Lambert-Eaton myasthenic syndrome caused by an L-type Ca2+ channel antagonist.

Japanese heart journal 20030101

Treatment for Lambert-Eaton myasthenic syndrome.

The Cochrane database of systematic reviews 20030101

Effect of thymol on kinetic properties of Ca and K currents in rat skeletal muscle.

BMC pharmacology 20030101

Raphé grafts and 3,4-diaminopyridine-evoked overflow of serotonin in the rat hippocampus after 5,7-dihydroxytryptamine lesions: evidence for 5-HT1A autoreceptors.

Neuroreport 20021028

Analysis of the pressor response to the K+ channel inhibitor 4-aminopyridine.

European journal of pharmacology 20021011

Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods.

International journal of pharmaceutics 20020821

Improvement of dy/dy dystrophic diaphragm by 3,4-diaminopyridine.

Muscle & nerve 20020701

The nature of the receptor site for the reversible K+ channel blocking by aminopyridines.

Biophysical chemistry 20020410

[Treatment of severe botulism with 3,4-diaminopyridine]].

Presse medicale (Paris, France : 1983) 20020406

Potassium channel KV alpha1 subunit expression and function in human detrusor muscle.

The Journal of urology 20020401

Action of Micrurus dumerilii carinicauda coral snake venom on the mammalian neuromuscular junction.

Toxicon : official journal of the International Society on Toxinology 20020201

Activation thresholds of K(V), BK andCl(Ca) channels in smooth muscle cells in pial precapillary arterioles.

Journal of vascular research 20020101

Role of K+ channels in L-6 myoblast migration.

Journal of muscle research and cell motility 20020101

Aminopyridines for symptomatic treatment in multiple sclerosis.

The Cochrane database of systematic reviews 20020101

[Lambert-Eaton myasthenic syndrome: diagnosis and treatment].

Clinical calcium 20011101

Expression and function of native potassium channel [K(V)alpha1] subunits in terminal arterioles of rabbit.

The Journal of physiology 20010801

[Quantitative evaluation of the effect of 3,4-diaminopyridine in a patient with Lambert-Eaton myasthenic syndrome using dynamic dynamometry].

Rinsho shinkeigaku = Clinical neurology 20010801

Theoretical analysis of the molecular determinants responsible for the K(+) channel blocking by aminopyridines.

Biophysical chemistry 20010615

Neuromuscular monitoring in myasthenic syndrome.

Anaesthesia 20010601

Electrophysiological analysis of the neurotoxic action of a funnel-web spider toxin, delta-atracotoxin-HV1a, on insect voltage-gated Na+ channels.

The Journal of experimental biology 20010201

Modulation of diaphragm action potentials by K(+) channel blockers.

Respiration physiology 20010201

Validation of a CE assay for the analysis of isomeric aminopyridines and diaminopyridines.

Journal of pharmaceutical and biomedical analysis 20010201

Neurogenic bladder in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.

Journal of the neurological sciences 20010115

[Proximal muscle weakness, depressed tendon reflexes and autonomic dysfunction: the Lambert-Eaton myasthenic syndrome].

Nederlands tijdschrift voor geneeskunde 20010113

Development and validation of a capillary electrophoresis assay for the determination of 3,4-diaminopyridine and 4-aminopyridine including related substances.

Journal of chromatography. A 20010112

Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.

Toxicon : official journal of the International Society on Toxinology 20010101

Aminopyridines for symptomatic treatment in multiple sclerosis.

The Cochrane database of systematic reviews 20010101

Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.

Toxicon : official journal of the International Society on Toxinology 20001001

Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations.

Toxicon : official journal of the International Society on Toxinology 19950401